2
6
1
↑2
↓6
—1
Evidence suggests Semaglutide maydecreaseType 2 diabetes.
9 studies (9 claims)
Emerging evidence
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| semaglutide (2.4 mg) | Increases - increased sharply | dispensations among adults without diabetes but prescribed WLMs | Human | adults without diabetes but prescribed WLMs | — | Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study. |
| semaglutide (2.0 mg) | Increases - increasing | dispensations among adults without diabetes but prescribed WLMs | Human | adults without diabetes but prescribed WLMs | — | Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study. |
| semaglutide | Decreases - would reduce | incident cases of diabetes | Human | 126 million eligible US adults | — | Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. |
| semaglutide | Decreases - showed remission of type 2 diabetes | type 2 diabetes | Human | — | — | A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. |
| Semaglutide | Decreases - constitutes an effective and widely used treatment | type 2 diabetes and obesity | Human | — | Not specified | Design and Biosynthesis of Ornithine 8-Containing Semaglutide Variants with a Click Chemistry-Modifiable Position 26. |
| oral semaglutide | No effect - approved | type 2 diabetes | Human | — | — | Oral GLP-1 Receptor Agonists for Weight Loss. |